Join
Live feed
·
PRReleasevia Quantisnow
NRX Pharmaceuticals Inc. logo

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

ByQuantisnow·Wall Street's wire, on your screen.
NRXP· NRX Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRXP (NRX Pharmaceuticals Inc.) and more on Quantisnow.